Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
73 hedge funds and large institutions have $44.8M invested in Adamas Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 13 closing their positions.
1,045% more call options, than puts
Call options by funds: $584K | Put options by funds: $51K
8% less funds holding
Funds holding: 79 → 73 (-6)
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
28% less capital invested
Capital invested by funds: $62.1M → $44.8M (-$17.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.45M |
| 2 |
Morgan Stanley
New York
|
+$2.16M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$757K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$704K |
| 5 |
JP Morgan Chase
New York
|
+$642K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.83M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.65M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.15M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$829K |
| 5 |
AC
Antara Capital
New York
|
-$640K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$130K | -34,200 | Closed |
|
77
Squarepoint
New York
| – | -$114K | -30,177 | Closed |
|
|
JG
78
Jefferies Group
New York
| – | -$107K | -28,135 | Closed |
|
79
Jane Street
New York
| – | -$79K | -20,918 | Closed |
|
|
BGIM
80
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
| – | -$70K | -17,127 | Closed |
|
81
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$54K | -14,336 | Closed |
|
|
HF
82
HRT Financial
New York
| – | -$43K | -11,432 | Closed |
|
|
PP
83
Paloma Partners
Greenwich,
Connecticut
| – | -$39K | -10,239 | Closed |
|
|
CHAM
84
Clear Harbor Asset Management
Stamford,
Connecticut
| – | -$18.6K | -4,920 | Closed |
|
85
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$11K | -2,811 | Closed |
|
86
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -300 | Closed |
|
ADMS Hedge Fund Activity: Q1 2020 in Review
73 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2020, worth a combined $44.8M — down 28% from $62.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADMS and 10 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 24 added.
The largest buyer was Armistice Capital, adding an estimated $2.45M. The largest seller was Stonepine Capital Management, cutting an estimated $4.83M.
- 73 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $44.8M of Adamas Pharmaceuticals stock for Q1 2020, down 28% quarter-over-quarter.
- 10 funds opened new Adamas Pharmaceuticals positions in Q1 2020 and 13 closed out, a net change of -3 holders.
- The largest Adamas Pharmaceuticals buyer in Q1 2020 was Armistice Capital, an estimated $2.45M added.
- The largest Adamas Pharmaceuticals seller in Q1 2020 was Stonepine Capital Management, an estimated $4.83M sold.
Based on aggregated 13F filings for Q1 2020.